New horizons in lung cancer management through ATR/CHK1 pathway modulation
Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling
has contributed to a new classification of lung cancer, driving advancements in research and …
has contributed to a new classification of lung cancer, driving advancements in research and …
MYC-induced replicative stress: a double-edged sword for cancer development and treatment
L Curti, S Campaner - International Journal of Molecular Sciences, 2021 - mdpi.com
MYC is a transcription factor that controls the expression of a large fraction of cellular genes
linked to cell cycle progression, metabolism and differentiation. MYC deregulation in tumors …
linked to cell cycle progression, metabolism and differentiation. MYC deregulation in tumors …
Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging …
Although several ATR inhibitors are in development, there are unresolved questions
regarding their differential potency, molecular signatures of patients with cancer for …
regarding their differential potency, molecular signatures of patients with cancer for …
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib
L Zhu, Z Chen, H Zang, S Fan, J Gu, G Zhang… - Cancer research, 2021 - AACR
Osimertinib (AZD9291 or TAGRISSO) is a promising and approved third-generation EGFR
tyrosine kinase inhibitor (TKI) for treating patients with advanced non–small cell lung cancer …
tyrosine kinase inhibitor (TKI) for treating patients with advanced non–small cell lung cancer …
Targeting squalene epoxidase interrupts homologous recombination via the ER stress response and promotes radiotherapy efficacy
Over 50% of all patients with cancer are treated with radiotherapy. However, radiotherapy is
often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene …
often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene …
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs
JS Wasserman, B Faezov, KR Patel… - Nature …, 2024 - nature.com
Abstract The Ser/Thr protein phosphatase 2 A (PP2A) regulates the dephosphorylation of
many phosphoproteins. Substrate recognition are mediated by B regulatory subunits. Here …
many phosphoproteins. Substrate recognition are mediated by B regulatory subunits. Here …
[HTML][HTML] Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells
J Biayna, I Garcia-Cao, MM Álvarez, M Salvadores… - PLoS …, 2021 - journals.plos.org
Analysis of cancer mutagenic signatures provides information about the origin of mutations
and can inform the use of clinical therapies, including immunotherapy. In particular …
and can inform the use of clinical therapies, including immunotherapy. In particular …
Exosomal miR-136-5p derived from anlotinib-resistant NSCLC cells confers anlotinib resistance in non-small cell lung cancer through targeting PPP2R2A
G Gu, C Hu, K Hui, H Zhang, T Chen… - International Journal …, 2021 - Taylor & Francis
Background Anlotinib resistance is a challenge for advanced non-small cell lung cancer
(NSCLC). Understanding the underlying mechanisms against anlotinib resistance is of great …
(NSCLC). Understanding the underlying mechanisms against anlotinib resistance is of great …
[HTML][HTML] PP2A B55α inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancer
Abstract PP2A B55α, encoded by PPP2R2A, acts as a regulatory subunit of the
serine/threonine phosphatase PP2A. Despite a frequent loss of heterozygosity of PPP2R2A …
serine/threonine phosphatase PP2A. Despite a frequent loss of heterozygosity of PPP2R2A …
A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer
The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in
breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease …
breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease …